Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson’s disease

By Jeong Hyun Yoon, Chiao-Yin Lee, MSc and Anthony Schapira, PhD
Published September 14, 2023
View Published Article

Output Details

Published September 14, 2023

Description
Perspective on the biochemical consequences of glucocerebrosidase 1 mutations in Parkinson’s disease
Identifier (DOI)
10.4103/1673-5374.382238
Tags
  • GBA (Glucocerebrosidase)
  • GBA1
  • L444P
  • Parkinson's disease
  • Review
Team
Team Schapira
Program
Collaborative Research Network
Theme
Neuro-Immune Interactions

Meet the Authors

Related Research

Lysosomal GCase (glucocerebrosidase) activity assay

Method to measure lysosomal GBA1 enzyme activity using 4-MUG substrate at low pH to minimize non-lysosomal GCase interference. GBA1 activity higher in purified lysosomes than whole cell extract, confirmed by CBE inhibitor abolishing 4-MUG hydrolysis.

View Protocol

(x6) GBA heterozygous and homozygous mutant fibroblast lines available to share

Cell lines deposited at ATCC used in a publication (10.1093/hmg/ddac233) include UCL-CTRL001, UCL-CTRL002, UCL-CTRL003, UCL-YCTRL001, UCL-E001K, UCL-N001S, and UCL-N002S, each with specific RRIDs.

View Lab Material

Lysosomal Glucocerebrosidase is needed for ciliary Hedgehog signaling: A convergent pathway to Parkinson’s disease

Mutations in LRRK2 and GBA1 are common in familial Parkinson’s disease. These mutations inhibit primary cilia formation, blocking Hedgehog signaling and reducing neuroprotective factors, contributing to PD pathogenesis.

View Article
View More Outputs